Clinical trials
Phase 3 Nervous System Diseases trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
48 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2007 | 2 |
| 2010 | 3 |
| 2011 | 4 |
| 2013 | 3 |
| 2014 | 4 |
| 2015 | 3 |
| 2016 | 6 |
| 2017 | 4 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 5 |
| 2022 | 1 |
| 2023 | 4 |
| 2024 | 3 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 26 |
| Terminated | 12 |
| Active, not recruiting | 8 |
| Unknown status | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AbbVie | 4 |
| Vanda Pharmaceuticals | 4 |
| GenSight Biologics | 3 |
| PTC Therapeutics | 3 |
| AstraZeneca | 2 |
| Auspex Pharmaceuticals, Inc. | 2 |
| Eli Lilly and Company | 2 |
| Hospira, now a wholly owned subsidiary of Pfizer | 2 |
| Ipsen | 2 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Nervous System Diseases | 48 |
| Central Nervous System Diseases | 17 |
| Brain Diseases | 13 |
| Neurodegenerative Diseases | 13 |
| Genetic Diseases, Inborn | 11 |
| Mental Disorders | 10 |
| Dementia | 9 |
| Genetic Diseases, X-Linked | 9 |
| Neurologic Manifestations | 9 |
| Alzheimer Disease | 8 |
Trials
Showing 1 to 25 of 48. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.